A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab
improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic
cancer compared to historical data. The safety of this combination treatment will also be
studied.